Actionable news
All posts from Actionable news
Actionable news in UTHR: United Therapeutics Corporation,

United Therapeutics Hurt By Competitive Pressure

Argus provided its outlook on United Therapeutics Corporation UTHR 1.22%, mentioning the negative effects of competitive pressures and regulatory delays. The company's primary drug, treprostinil, is used to treat patients suffering from pulmonary arterial hypertension (PAH). The company has expanded its presence in the domestic PAH market with three forms of treprostinil, and has now added a pill version, Orenitram, to this franchise.

The analysts noted their concerns that Orenitram is facing increased competitive pressure from Actelion's Uptravi, despite the company's strong 2Q16 results. The company is also experiencing regulatory delays with its new subcutaneous implantable device for treprostinil, which is expected to replace the current pump system.

Moreover, Argus views the unexpected resignation of two senior executives (Co-CEO Roger Jeffs and COO David Zaccardelli) after the release of first-quarter earnings in April, as a negative sign and thus reiterates its Hold rating on shares.

Jul 2016JP MorganMaintainsNeutral
Jun 2016H.C. WainwrightDowngradesBuyNeutral
May 2016Argus ResearchDowngradesBuyHold

© 2016 Benzinga does not provide investment advice. All rights reserved.